<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35253557</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>7-8</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches.</ArticleTitle><Pagination><StartPage>517</StartPage><EndPage>526</EndPage><MedlinePgn>517-526</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2022.2039713</ELocationID><Abstract><AbstractText><i>Objective</i>: Amyotrophic lateral sclerosis (ALS) is a multi-system disorder characterized primarily by motor neuron degeneration, but may be accompanied by cognitive dysfunction. Statistically appropriate criteria for establishing cognitive impairment (CI) in ALS are lacking. We evaluate quantile regression (QR), that accounts for age and education, relative to a traditional two standard deviation (SD) cutoff for defining CI. <i>Methods</i>: QR of cross-sectional data from a multi-center North American Control (NAC) cohort of 269 healthy adults was used to model the 5<sup>th</sup> percentile of cognitive scores on the Edinburgh Cognitive and Behavioral ALS Screen (ECAS). The QR approach was compared to traditional two SD cutoff approach using the same NAC cohort (2SD-NAC) and to existing UK-based normative data derived using the 2SD approach (2SD-UK) to assess the impact of cohort selection and statistical model in identifying CI in 182 ALS patients. <i>Results</i>: QR-NAC models revealed that age and education impact cognitive performance on the ECAS. Based on QR-NAC normative cutoffs, the frequency of CI in the 182 PENN ALS patients was 15.9% for ALS specific, 12.6% for ALS nonspecific, and 15.4% for ECAS total. This frequency of CI is substantially more conservative in comparison to the 2SD-UK (20.3%-34.6%) and modestly more conservative to the 2SD-NAC (14.3%-16.5%) approaches for estimating CI. <i>Conclusions</i>: The choice of normative cohort has a substantial impact and choice of statistical method a modest impact on defining CI in ALS. This report establishes normative ECAS thresholds to identify whether ALS patients in the North American population have CI.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McMillan</LastName><ForeName>Corey T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wuu</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rascovsky</LastName><ForeName>Katya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cosentino</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grossman</LastName><ForeName>Murray</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7447-6218</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elman</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Colin</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0618-5854</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosario</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stark</LastName><ForeName>Jessica H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granit</LastName><ForeName>Volkan</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Briemberg</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chenji</LastName><ForeName>Sneha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0635-1528</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dionne</LastName><ForeName>Annie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Universit&#xe9; Laval, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genge</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnston</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Canada, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korngut</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoesmith</LastName><ForeName>Christen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>London Health Sciences Centre, Western University, London, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinman</LastName><ForeName>Lorne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Canadian ALS Neuroimaging Consortium (CALSNIC)</CollectiveName></Author><Author ValidYN="Y"><LastName>Kalra</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Canada, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benatar</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4241-5135</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS092091</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG066597</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS105479</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS107027</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS-FTD</Keyword><Keyword MajorTopicYN="N">Cognition</Keyword><Keyword MajorTopicYN="N">ECAS</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">neuropsychology</Keyword><Keyword MajorTopicYN="N">normative data</Keyword><Keyword MajorTopicYN="N">risk</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>7</Day><Hour>8</Hour><Minute>46</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35253557</ArticleId><ArticleId IdType="mid">NIHMS1787254</ArticleId><ArticleId IdType="pmc">PMC9448823</ArticleId><ArticleId IdType="doi">10.1080/21678421.2022.2039713</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis and other motor neuron disorders. 2000. p. 293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein LH, Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol. 2013;12:368&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">23518330</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. Epub 2017 Jan 5.:1&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Elamin M, Bede P, Byrne S, et al. Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology. 2013;80:1590&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pubmed">23553481</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Newton J, Niven E, Foley J, Bak TH. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:9&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">23781974</ArticleId></ArticleIdList></Reference><Reference><Citation>Niven E, Newton J, Foley J, et al. Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): A cognitive tool for motor disorders. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:172&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">25967542</ArticleId></ArticleIdList></Reference><Reference><Citation>De Icaza Valenzuela M&#xf3;nica M, H BT, Suvankar P, Sharon A. The Edinburgh Cognitive and Behavioral ALS screen: relationship to age, education, IQ and the Addenbrooke&#x2019;s Cognitive Examination-III. Amyotroph Lateral Scler Frontotemporal Degener. 2nd ed. Taylor &amp; Francis; 2018;00:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">30369272</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojsi F, Caiazzo G, Siciliano M, et al. Microstructural correlates of Edinburgh Cognitive and Behavioural ALS Screen (ECAS) changes in amyotrophic lateral sclerosis. Psychiatry Res Neuroimaging. 2019;288:67&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">30987770</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory JM, McDade K, Bak TH, et al. Executive, language and fluency dysfunction are markers of localised TDP-43 cerebral pathology in non-demented ALS. Journal of Neurology, Neurosurgery, and Psychiatry. BMJ Publishing Group Ltd; Epub 2019 Sep 12.:jnnp&#x2013;2019&#x2013;320807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6996101</ArticleId><ArticleId IdType="pubmed">31515300</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker LA, Schr&#xf6;der CD, Spreij LA, et al. Derivation of norms for the Dutch version of the Edinburgh cognitive and behavioral ALS screen. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:19&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">30314420</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; D, Burkhardt C, Abdulla S, et al. The Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen: a cross-sectional comparison of established screening tools in a German-Swiss population. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:16&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">25292386</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Salas T, Fern&#xe1;ndez MC, et al. Spanish adaptation of the edinburgh cognitive and behavioral amyotrophic lateral sclerosis screen (ECAS). Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:74&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">29212378</ArticleId></ArticleIdList></Reference><Reference><Citation>Poletti B, Solca F, Carelli L, et al. Cognitive-behavioral longitudinal assessment in ALS: the Italian Edinburgh Cognitive and Behavioral ALS screen (ECAS). Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:387&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">29804470</ArticleId></ArticleIdList></Reference><Reference><Citation>Loose M, Burkhardt C, Aho-&#xd6;zhan H, et al. Age and education-matched cut-off scores for the revised German/Swiss-German version of ECAS. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:374&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">27027323</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto-Grau M, Burke T, Lonergan K, et al. Screening for cognitive dysfunction in ALS: validation of the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) using age and education adjusted normative data. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:99&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">27894201</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalra S, Khan MU, Barlow L, et al. The Canadian ALS Neuroimaging Consortium (CALSNIC) - a multicentre platform for standardized imaging and clinical studies in ALS. medRxiv 2020. p. 1&#x2013;19.</Citation></Reference><Reference><Citation>Benatar M, Wuu J, Peng L. Reference data for commonly used sensory and motor nerve conduction studies. Muscle Nerve. 2009;40:772&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">19827092</ArticleId></ArticleIdList></Reference><Reference><Citation>Muggeo VMR, Sciandra M, Tomasello A, Calvo S. Estimating growth charts via nonparametric quantile regression: a practical framework with application in ecology. Environ Ecol Stat. Springer US; 2013;20:519&#x2013;531.</Citation></Reference><Reference><Citation>Hodgins F, Mulhern S, Abrahams S. The clinical impact of the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) and neuropsychological intervention in routine ALS care. Amyotroph Lateral Scler Frontotemporal Degener. 2019;12:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31612737</ArticleId></ArticleIdList></Reference><Reference><Citation>Placek K, Benatar M, Wuu J, et al. Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis. EMBO Mol Med. John Wiley &amp; Sons, Ltd; 2020;15:e12595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799365</ArticleId><ArticleId IdType="pubmed">33270986</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg LH, Sorenson E, Gronseth G, et al. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology. 2019;92:e1610&#x2013;e1623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology; 2005;65:586&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">16116120</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank B, Haas J, Heinze HJ, Stark E, M&#xfc;nte TF. Relation of neuropsychological and magnetic resonance findings in amyotrophic lateral sclerosis: evidence for subgroups. Clin Neurol Neurosurg. 1997;99:79&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">9213049</ArticleId></ArticleIdList></Reference><Reference><Citation>Ardila A Toward the development of a cross-linguistic naming test. Arch Clin Neuropsychol. 2007;22:297&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">17303376</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates E, D&#x2019;Amico S, Jacobsen T, et al. Timed picture naming in seven languages. Psychon Bull Rev. 2003;10:344&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392189</ArticleId><ArticleId IdType="pubmed">12921412</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosselli M, Ardila A, SALVATIERRA J, MARQUEZ M, Matos L, WEEKES VA. A cross-linguistic comparison of verbal fluency tests. Int J Neurosci. 2002;112:759&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">12325314</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor LJ, Brown RG, Tsermentseli S, et al. Is language impairment more common than executive dysfunction in amyotrophic lateral sclerosis? Journal of Neurology, Neurosurgery, and Psychiatry. 2013;84:494&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">23033353</ArticleId></ArticleIdList></Reference><Reference><Citation>Libon DJ, McMillan C, Avants B, et al. Deficits in concept formation in amyotrophic lateral sclerosis. 2012;26:422&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3516292</ArticleId><ArticleId IdType="pubmed">22612577</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash S, Olm C, McMillan CT, et al. Deficits in sentence expression in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:31&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4372458</ArticleId><ArticleId IdType="pubmed">25482157</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash S, Menaged A, Olm C, et al. Narrative discourse deficits in amyotrophic lateral sclerosis. Neurology. 2014;83:520&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4142005</ArticleId><ArticleId IdType="pubmed">24991038</ArticleId></ArticleIdList></Reference><Reference><Citation>Nevler N, Ash S, McMillan C, et al. Automated analysis of natural speech in amyotrophic lateral sclerosis spectrum disorders. Neurology. 2020;95:e1629&#x2013;e1639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7713725</ArticleId><ArticleId IdType="pubmed">32675077</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Caselli RJ. Appraisal of cognition in preclinical Alzheimer&#x2019;s disease: a conceptual review. Neurodegener Dis Manag. 2012;2:183&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3395065</ArticleId><ArticleId IdType="pubmed">22798965</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Libon DJ, Toledo JB, et al. Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. Acta Neuropathol. 2012;123:395&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3595560</ArticleId><ArticleId IdType="pubmed">22210083</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y Cognitive reserve. Neuropsychologia. 2009;47:2015&#x2013;2028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739591</ArticleId><ArticleId IdType="pubmed">19467352</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavrencic LM, Churches OF, Keage HAD. Cognitive reserve is not associated with improved performance in all cognitive domains. Appl Neuropsychol Adult. 2017;25:473&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">28594578</ArticleId></ArticleIdList></Reference><Reference><Citation>Placek K, Massimo L, Olm C, et al. Cognitive reserve in frontotemporal degeneration: Neuroanatomic and neuropsychological evidence. Neurology. 2016;87:1813&#x2013;1819.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5089523</ArticleId><ArticleId IdType="pubmed">27683847</ArticleId></ArticleIdList></Reference><Reference><Citation>Crockford C, Newton J, Lonergan K, et al. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology. Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology; 2018;91:e1370&#x2013;e1380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6177274</ArticleId><ArticleId IdType="pubmed">30209236</ArticleId></ArticleIdList></Reference><Reference><Citation>Crockford C, Newton J, Lonergan K, et al. Measuring reliable change in cognition using the Edinburgh Cognitive and Behavioural ALS Screen (ECAS). Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:65&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6510059</ArticleId><ArticleId IdType="pubmed">29214872</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>